Sanofi/AstraZeneca Win Beyfortus Approval To Prevent RSV In US Infants

Prophylactic Antibody A Key Asset In Sanofi’s Vaccine Portfolio

 
• By Mandy Jackson
  
Portrait of asian parent hands holding newborn baby
Beyfortus is approved for newborns and toddlers in their second RSV season • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip